Moderna FY2025 EPS Forecast Decreased by Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Leerink Partnrs dropped their FY2025 earnings estimates for shares of Moderna in a report released on Sunday, November 17th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($9.90) per share for the year, down from their previous estimate of ($9.89). The consensus estimate for Moderna’s current full-year earnings is ($9.43) per share.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the business posted ($1.39) earnings per share.

A number of other equities research analysts have also recently issued reports on MRNA. Berenberg Bank started coverage on shares of Moderna in a research note on Tuesday. They issued a “hold” rating and a $42.00 price target on the stock. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research report on Monday, November 4th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Finally, Bank of America dropped their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $84.00.

Moderna Stock Performance

MRNA opened at $36.94 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market capitalization of $14.22 billion, a PE ratio of -6.41 and a beta of 1.69. The business has a fifty day simple moving average of $56.98 and a 200 day simple moving average of $95.46. Moderna has a 1 year low of $35.80 and a 1 year high of $170.47.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 2,930 shares of company stock valued at $217,170. 15.20% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Hedge funds have recently made changes to their positions in the company. State Street Corp raised its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Moderna in the 3rd quarter valued at $23,825,000. International Assets Investment Management LLC grew its holdings in Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after acquiring an additional 316,552 shares during the period. Finally, Matrix Capital Management Company LP boosted its position in shares of Moderna by 60.8% during the 1st quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock valued at $77,789,000 after purchasing an additional 276,000 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.